Semaglutide in Ozempic and Wegovy may improve taste sensitivity and alter brain response to sweet tastes in obese women, according to ENDO 2024 research.
GLP-1 receptor agonist semaglutide, found in Ozempic and Wegovy, may improve taste sensitivity and alter brain response to sweet tastes in women with obesity, according to research presented at ENDO 2024. The study showed that the drug changed gene expression in the tongue related to taste perception and influenced how the brain responds to sweet tastes. The findings could provide a new understanding of how these drugs help with weight loss.
June 01, 2024
3 Articles